Guixin Shi

-- More than 20 years of research and industrial experience in biomedical engineering, biomaterials, targeted cell isolation and cell therapy. -- Co-founder of Diagnologix which has 7 patents approved/pending on approval and has received 5 SBIR grants from NIH. -- Primary inventor of BUBLES technology, a microbubble-based cell isolation platform, which enables the efficient isolation of CTCs, NK cells, T cells, rare stem cells, etc., from blood in a closed automated system. -- A bead-free technology for cell selection, cell activation, virus transduction and cell expansion in cell therapy application. -- Multi-marker selection of specific T cell subtype (Tnaive, Treg, Tscm, etc.) for CAR-T therapy.